NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
May 17, 2022 07:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022
May 12, 2022 17:00 ET
|
NeuBase Therapeutics, Inc.
Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic dystrophy type 1 (DM1) candidate; new preclinical...
NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
May 02, 2022 16:30 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
March 13, 2022 19:00 ET
|
NeuBase Therapeutics, Inc.
A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses...
NeuBase to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 07, 2022 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference
February 28, 2022 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022
February 10, 2022 19:00 ET
|
NeuBase Therapeutics, Inc.
Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and...
NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer
January 10, 2022 16:02 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors
January 05, 2022 16:02 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021
December 23, 2021 16:01 ET
|
NeuBase Therapeutics, Inc.
Validated ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies; the Company’s delivery shuttle enables...